CELG
Celgene Corp (CELG)

What company owns Celgene?

Bristol Myers Squibb
Celgene/Parent organizations
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by …

What happened to my Celgene stock?

Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.”

Is Celgene a publicly traded company?

Celgene became a subsidiary of BMS and is no longer a publicly traded company on its own.

Can you still buy Celgene stock?

Shareholders of both companies have approved the transaction. The only real hurdle remaining is to obtain regulatory approvals for the acquisition, which shouldn’t be a problem. Within the next three months or so, Celgene’s shares will no longer trade on the Nasdaq stock exchange.

Is BMY a buy or sell?

Yes, BMY stock is a buy right now, with some caveats.

Can I still buy Celgene stock?

How much is Celgene worth?

Celgene’s shares traded at over $74 per share, and its market capitalization was valued at over US$51.8 billion in November 2018.

What was the stock price of Celgene last month?

Celgene’s stock couldn’t escape the market’s wrath toward biotech last month. The biotech company racked up a trio of clinical hits last month, sparking a double-digit rally in its shares. Celgene’s self-inflicted wounds haven’t sat well with investors this year. Post-earnings call upgrades are providing some lift.

What kind of company is Celgene, Inc.?

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. The Fool has written over 1000 articles on Celgene.

How much did Bristol Myers Squibb pay for Celgene?

In the first megablockbuster deal of the year, Bristol-Myers Squibb takes out oncology giant Celgene in a deal worth $74 billion. Celgene’s stock couldn’t escape the market’s wrath toward biotech last month.

When did Celgene pay top dollar for Juno?

Celgene paid top dollar for Juno Therapeutics last month, but the biotech heavyweight may end up with buyer’s remorse. Here’s why. CELG earnings call for the period ending December 31, 2018. CELG earnings call for the period ending September 30, 2018.